载体介导的艾美耳球虫微线体蛋白疫苗的研制现状  

The status in the research of vector-based vaccine of microneme protein of Eimeria

作　　者：李文桂[1] 陈雅棠[1] LI Wen-gui;CHEN Ya-tang(Institute of Infectious and Parasitic Diseases,the First Affiliated Hospital,Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院传染病寄生虫病研究所,重庆400016

出　　处：《中国病原生物学杂志》2022年第7期848-851,共4页Journal of Pathogen Biology

基　　金：国家自然科学基金项目(No.30801052,30671835,30500423,30200239)。

摘　　要：艾美耳球虫是鸡球虫病的病原体,疫苗研发是当前的热点领域之一。微线体蛋白免疫原性良好,本研究就卡介苗(rBCG-AMA1/RB)、乳酸乳球菌(rLL-AMA1)、植物乳杆菌(rLp-EtMIC1/EtMIC2/TA4-AMA1)、鼠伤寒沙门氏菌(rSt-5401/EnMIC2/MIC5)、根癌农杆菌(rAt-MIC2)、酵母(rPP-EtMIC2)和鸡痘病毒(rFPV-RB)等载体介导的艾美耳球虫微线体蛋白疫苗的研究进展进行综述。Eimeria is one type of pathogen agents casuing chicken coccidiosis,it recently becomes highlight to control this virus by use of the vaccine.The microneme protein has ideal immunogenicity,it’s outlined on the status in the research of vaccine of microneme protein of Eimeria mediated by bacteria such as BCG(rBCG-AMA1/RB),Lactococcus lactis(rLL-AMA1),Lactobacillus plantarum(rLp-EtMIC1/EtMIC2/TA4-AMA1),Salmonella typhimurium(rSt-5401/EnMIC2/MIC5),Agrobacteria tumefaciens(rAt-MIC2),Pichia(rPP-EtMIC2),and virus such as Fowlpox virus(rFPV-RB).

关 键 词：艾美耳球虫 微线体蛋白 疫苗 综述 

分 类 号：S858.33[农业科学—临床兽医学] R382.32[农业科学—兽医学]